Skip to main content

Table 6 Overall survival and progression-free survival from the start of second-line targeted therapy according to progression-free survival on first-line targeted therapy

From: Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry

Second-line targeted therapy n OS PFS
Median (95% CI) P Median (95% CI) P
Everolimus
 PFS1 < 9 months 230 12.7 months (10.5–14.9) < 0.001 5.0 months (3.9–6.1) < 0.001
 PFS1 ≥ 9 months 290 19.7 months (16.4–23.0) 7.3 months (5.9–8.8)
Sorafenib
 PFS1 < 9 months 123 13.8 months (7.9–19.7) 0.083 5.4 months (4.1–6.7) 0.628
 PFS1 ≥ 9 months 117 17.5 months (14.6–20.4) 6.2 months (5.0–7.4)
Sunitinib
 PFS1 < 9 months 136 12.9 months (5.7–20.1) 0.171 5.0 months (4.0–6.0) 0.571
 PFS1 ≥ 9 months 92 15.7 months (9.5–22.0) 6.9 months (4.0–9.7)
  1. 95% CI 95% confidence interval, OS overall survival, PFS progression-free survival, PFS1 progression-free survival on first-line targeted therapy